October 14, 2026 update. ALSTARS is a Phase 2/3 trial, and Coya completed its planned enrollment of 120 participants on Oct 5, 2026. Topline 24-week data is now guided for early Q2 2027, not 1Q 2027 (8-K, Oct 5, 2026). On Oct 14 Coya said it will start an open-label extension in November 2026 and has pushed the FTD Phase 2 start from 2H 2026 into 2027; runway guidance remains into 2H 2027 (Coya via Business Wire, Oct 14, 2026). Cash was $43.2M at June 30, 2026 (10-Q). The share price was about $4.22 intraday on Oct 14, vs. ~$4.87 on Jul 14.
The Thesis in Brief
Coya Therapeutics, Inc. (Nasdaq: COYA) is the clinical-stage name on our 2026 watch list built around one of biology's most validated — and until recently under-exploited — ideas: that the immune system's regulatory T cells (Tregs) can be enlisted to switch off the chronic inflammation that drives neurodegeneration. Founded in 2020 and Houston-based, Coya went public in December 2022 (its shares priced December 28, 2022 and began trading December 29, 2022).
The appeal is its capital efficiency and partner validation. Lead asset COYA 302 combines two well-characterized, already-approved components — low-dose IL-2 and abatacept — into a single subcutaneous biologic, and a global generics-and-biologics heavyweight, Dr. Reddy's Laboratories, is funding and will commercialize the ALS program across major Western markets while Coya keeps ex-US and pipeline rights. FDA Fast Track in ALS and $43.2M of cash at June 30, 2026 are guided to fund the runway into 2H 2027, past the pivotal readout. The trade-off is stark: value is concentrated in one lead program, the Phase 2/3 topline readout in early Q2 2027 is largely binary, and future dilution is a base-case assumption.
The Science: What the Treg Platform Actually Does
Regulatory T cells are the immune system's brakes — the cells that keep inflammation in check and prevent the body from attacking its own tissue. A growing body of research (built on the Nobel-recognized biology of Treg suppression) links dysfunctional or exhausted Tregs to the chronic, self-sustaining inflammation seen in neurodegenerative and systemic inflammatory diseases. Coya's core hypothesis is that restoring Treg function can slow the underlying disease process rather than merely treating symptoms.
Coya pursues that goal across three complementary modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The biologics program is the most advanced and anchors the clinical story today, while the exosome and autologous cell-therapy platforms remain earlier-stage.
The premise is a shift in target: rather than chase a single misfolded protein, COYA 302 aims to restore the immune system's own ability to keep neuro-inflammation in check.
The flagship candidate, COYA 302, is a subcutaneous combination biologic pairing low-dose interleukin-2 (IL-2) — which supports and expands Treg populations — with CTLA4-Ig (abatacept), which dampens inflammatory T-cell and myeloid signaling. The dual mechanism is designed to enhance Treg function while suppressing inflammation at the same time. Because both components are already approved drugs used in other settings, their individual safety profiles are relatively well understood, which the company frames as a de-risking feature of the combination.
Pipeline: A Lead Combination Plus Optionality
1. COYA 302 for ALS (lead)
The lead indication is amyotrophic lateral sclerosis (ALS) — a relentlessly progressive, uniformly fatal motor-neuron disease with enormous unmet need. COYA 302 is being evaluated in the Phase 2/3 ALSTARS trial (NCT07161999), which completed planned enrollment of 120 participants in October 2026, and in May 2026 the program received FDA Fast Track Designation in ALS (granted May 11, 2026), which can support more frequent FDA interaction and eligibility for expedited review pathways. Topline data from the 24-week double-blind phase is guided for early Q2 2027 — the key value-inflection event for the company.
2. COYA 302 for Frontotemporal Dementia (FTD)
Coya is expanding COYA 302 into frontotemporal dementia (FTD), with its IND accepted; in October 2026 Coya moved the planned Phase 2 start from 2H 2026 into 2027 to prioritize ALS. FTD is a second, distinct neurodegenerative indication that leverages the same mechanism and combination, broadening the platform story beyond a single disease.
3. COYA 303 & Earlier-Stage Platforms
COYA 303 is a preclinical combination pairing low-dose IL-2 with a GLP-1 receptor agonist, aimed at peripheral and CNS inflammatory conditions; in vivo data is expected in the second half of 2026. Behind it sit the earlier-stage Treg-derived exosome and autologous Treg cell therapy platforms. For clarity: the active, company-sponsored clinical indications for COYA 302 are ALS and FTD — references to Alzheimer's or Parkinson's relate to supportive or exploratory investigator work, not active Coya-run COYA 302 trials.
Catalysts on the Horizon
Regulatory Standing
- FDA Fast Track Designation for COYA 302 in ALS (granted May 11, 2026) — supports closer FDA engagement and potential eligibility for expedited review pathways.
- IND accepted for the COYA 302 Phase 2a program in frontotemporal dementia, with the trial start now expected in 2027.
- Development strategy anchored by a combination of two already-approved components (low-dose IL-2 and abatacept), whose established individual safety profiles the company frames as a de-risking feature.
Financials & Structure
Coya reported cash and cash equivalents of $43.2M as of June 30, 2026 (10-Q), and on October 14, 2026 reiterated that cash should fund operations into the second half of 2027, beyond the early Q2 2027 ALSTARS readout. The stock was about $4.22 intraday on October 14, 2026. Investors should still expect the company to need more capital beyond that runway, so future dilution remains a base-case assumption. In January 2026, Dr. Reddy's led an $11.1M private placement (about $10M from DRL), underscoring partner commitment while adding shares.
The Dr. Reddy's Partnership
In November 2023, Coya signed an exclusive Development & License Agreement with Dr. Reddy's Laboratories (DRL) for COYA 302 in ALS. Under the deal, DRL holds commercialization rights in the US, Canada, EU and UK, while Coya retains Japan, Mexico and South America plus its broader pipeline. The economics include up to approximately $40M in development and regulatory milestones, up to roughly $677.25M in sales-based milestones, and low-to-mid-teens royalties on net sales. For a company of Coya's size, having a global partner fund and eventually commercialize the lead indication across major Western markets is the single most important external validation of the thesis — though the headline milestone figures are contingent, back-end-loaded, and far from guaranteed.
Bull vs. Bear
▲ The Bull Case
- Capital-efficient combination of two already-approved components (low-dose IL-2 + abatacept), reducing single-molecule safety uncertainty.
- Marquee Dr. Reddy's partnership funds and will commercialize ALS across the US, Canada, EU and UK.
- FDA Fast Track in ALS plus retained ex-US and pipeline optionality (FTD, COYA 303, exosomes).
- Nobel-validated Treg biology addressing indications with severe unmet need.
- $43.2M cash (June 30, 2026) guided to fund the runway past the early Q2 2027 readout; enrollment complete.
▼ The Bear Case
- Heavy single lead-program concentration — value hinges on COYA 302 in ALS.
- Phase 2 trial risk; ALS is a graveyard of failed drugs and the early Q2 2027 readout is largely binary.
- Likely future dilution to fund the broader pipeline beyond current runway.
- FTD trial start slipped from 2H 2026 into 2027.
- Milestone economics are contingent and back-end-loaded — not near-term cash.
Frequently Asked Questions
What does Coya Therapeutics do?
Coya is a clinical-stage biotech developing proprietary therapies that enhance regulatory T cell (Treg) function to suppress the chronic inflammation underlying neurodegenerative and systemic inflammatory diseases. It works across three modalities — Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy — with a lead program in ALS.
What is COYA 302?
COYA 302 is Coya's lead asset: a subcutaneous combination biologic of low-dose IL-2 plus CTLA4-Ig (abatacept). The dual mechanism enhances Treg function while dampening inflammation. It is in a Phase 2 trial (ALSTARS) for ALS — where it received FDA Fast Track Designation in May 2026 — and a Phase 2 study in frontotemporal dementia (FTD) is now expected to start in 2027.
What is the Dr. Reddy's partnership worth?
Coya's November 2023 exclusive Development & License Agreement with Dr. Reddy's Laboratories (DRL) covers COYA 302 in ALS. DRL holds US/Canada/EU/UK commercialization rights; Coya retains Japan, Mexico and South America. The economics include up to ~$40M in development/regulatory milestones, up to ~$677.25M in sales-based milestones, and low-to-mid-teens royalties. In January 2026, DRL also led an $11.1M private placement (~$10M from DRL). Milestone figures are contingent and back-end-loaded.
When is Coya's ALSTARS data?
Coya has guided to an ALSTARS Phase 2/3 topline readout in early Q2 2027 (enrollment completed October 2026) — the key, largely binary value-inflection event for the company. Its cash runway is guided into the second half of 2027, through that readout.
What are the main risks?
We don't give buy/sell recommendations. Coya is a clinical-stage biotech whose value is concentrated in a single lead program facing a largely binary Phase 2 readout, and it carries clinical, regulatory and financing (dilution) risk — including the potential loss of the entire investment. Do your own research and consult a licensed financial professional. See the full disclosure below.